Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RIVAROXABAN Cause Interstitial lung disease? 318 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 318 reports of Interstitial lung disease have been filed in association with RIVAROXABAN (Rivaroxaban). This represents 0.2% of all adverse event reports for RIVAROXABAN.

318
Reports of Interstitial lung disease with RIVAROXABAN
0.2%
of all RIVAROXABAN reports
60
Deaths
206
Hospitalizations

How Dangerous Is Interstitial lung disease From RIVAROXABAN?

Of the 318 reports, 60 (18.9%) resulted in death, 206 (64.8%) required hospitalization, and 38 (11.9%) were considered life-threatening.

Is Interstitial lung disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RIVAROXABAN. However, 318 reports have been filed with the FAERS database.

What Other Side Effects Does RIVAROXABAN Cause?

Gastrointestinal haemorrhage (20,041) Haemorrhage (6,571) Epistaxis (5,629) Rectal haemorrhage (4,501) Off label use (4,463) Haematuria (4,387) Upper gastrointestinal haemorrhage (4,247) Cerebrovascular accident (4,111) Anaemia (3,907) Acute kidney injury (3,735)

What Other Drugs Cause Interstitial lung disease?

METHOTREXATE (3,049) RITUXIMAB (2,458) PEMBROLIZUMAB (2,113) PREDNISONE (1,850) CYCLOPHOSPHAMIDE (1,725) NIVOLUMAB (1,538) AMIODARONE (1,421) DOXORUBICIN (1,352) ETANERCEPT (1,267) ADALIMUMAB (1,250)

Which RIVAROXABAN Alternatives Have Lower Interstitial lung disease Risk?

RIVAROXABAN vs RIVASTIGMINE RIVAROXABAN vs RIVOTRIL RIVAROXABAN vs RIZATRIPTAN RIVAROXABAN vs ROACTEMRA RIVAROXABAN vs ROCURONIUM

Related Pages

RIVAROXABAN Full Profile All Interstitial lung disease Reports All Drugs Causing Interstitial lung disease RIVAROXABAN Demographics